Page 5 - 2019_12-Haematologica-web

Table of Contents
Volume 104, Issue 12: December 2019
Cover Figure
haematologica Journal of the Ferrata Storti Foundation
Buffy coat smear from a patient with bone marrow relapse of malignant melanoma showing granules of melanin pigment in the cytoplasm of a neutrophil. Courtesy of Prof. Rosangela Invernizzi.
Editorials
2325 A new target for fetal hemoglobin reactivation Angela Rivers et al.
2327 Are we ready to use precision medicine in chronic myeloid leukemia practice? Dennis Dong Hwan Kim
2330 DNA damage on the DOCK in FLT3-ITD-driven acute myeloid leukemia Ruchi Pandey and Reuben Kapur
2332 Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia Tatjana Stankovic
2335 Teaming up for CAR-T cell therapy Ralph Wäsch et al.
Review Articles
2337 MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications Ruben A.L. de Groen et al.
2349 Novel evidence for a greater burden of ambient air pollution on cardiovascular disease Pier Mannuccio Mannucci et al.
Guideline Article
2358 Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network Philippe Moreau et al.
Articles
Red Cell Biology & its Disorders
2361 Disruption of the MBD2-NuRD complex but not MBD3-NuRD induces high level HbF expression in human adult erythroid cells Xiaofei Yu et al.
2372 Genetic disarray follows mutant KLF1-E325K expression in a congenital dyserythropoietic anemia patient Lilian Varricchio et al.
Myelodysplastic Syndromes
2382 Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study
Tatiana Raskovalova et al.
Myeloproliferative Neoplasms
2391 Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis Alberto Ferrari et al.
Chronic Myeloid Leukemia
2400 Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors Georgios Nteliopoulos et al.
Haematologica 2019; vol. 104 no. 12 - December 2019 http://www.haematologica.org/